Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gabriele Hoelscher"'
Autor:
Delphina Gomes, Andreas Beyerlein, Katharina Katz, Gabriele Hoelscher, Uta Nennstiel, Bernhard Liebl, Klaus Überla, Rüdiger von Kries
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfi
Externí odkaz:
https://doaj.org/article/6f82bbee4c6343d49c07c086397072dc
Autor:
Andreas Beyerlein, Bernhard Liebl, Gabriele Hoelscher, Uta Nennstiel, Klaus Ueberla, Katharina Katz, Delphina Gomes, Ruediger von Kries
BackgroundThe effect of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e433cc689019a5572e917447592d530
https://doi.org/10.1101/2021.08.19.21262266
https://doi.org/10.1101/2021.08.19.21262266
Autor:
Katharina Katz, Andreas Beyerlein, Rüdiger von Kries, Delphina Gomes, Bernhard Liebl, Uta Nennstiel, Klaus Überla, Gabriele Hoelscher
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE, Vol 16, Iss 11, p e0259370 (2021)
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE, Vol 16, Iss 11, p e0259370 (2021)
Background The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfi
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.